DK2205737T3 - Mikromirer - Google Patents
MikromirerInfo
- Publication number
- DK2205737T3 DK2205737T3 DK08801378.4T DK08801378T DK2205737T3 DK 2205737 T3 DK2205737 T3 DK 2205737T3 DK 08801378 T DK08801378 T DK 08801378T DK 2205737 T3 DK2205737 T3 DK 2205737T3
- Authority
- DK
- Denmark
- Prior art keywords
- micromirers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97749707P | 2007-10-04 | 2007-10-04 | |
US97921707P | 2007-10-11 | 2007-10-11 | |
US2806208P | 2008-02-12 | 2008-02-12 | |
EP08104780 | 2008-07-17 | ||
PCT/DK2008/000344 WO2009043353A2 (en) | 2007-10-04 | 2008-10-03 | Micromirs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2205737T3 true DK2205737T3 (da) | 2013-05-21 |
Family
ID=40526747
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12191739.7T DK2623599T3 (da) | 2007-10-04 | 2008-10-03 | Mikromirer |
DK08801378.4T DK2205737T3 (da) | 2007-10-04 | 2008-10-03 | Mikromirer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12191739.7T DK2623599T3 (da) | 2007-10-04 | 2008-10-03 | Mikromirer |
Country Status (17)
Country | Link |
---|---|
US (5) | US8906871B2 (da) |
EP (5) | EP3492594A1 (da) |
JP (2) | JP6035010B2 (da) |
KR (1) | KR101889518B1 (da) |
CN (1) | CN101821391B (da) |
AU (1) | AU2008306327B2 (da) |
CA (1) | CA2701547C (da) |
DK (2) | DK2623599T3 (da) |
EA (1) | EA019939B1 (da) |
ES (3) | ES2689508T3 (da) |
IL (2) | IL204254A (da) |
MX (1) | MX2010003299A (da) |
MY (1) | MY156951A (da) |
NZ (1) | NZ583677A (da) |
PL (1) | PL2623598T3 (da) |
WO (2) | WO2009043353A2 (da) |
ZA (1) | ZA201002040B (da) |
Families Citing this family (250)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
JP4943322B2 (ja) | 2004-05-04 | 2012-05-30 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 標的細胞中のウイルスゲノム量を減少させるための方法および組成物 |
ES2526787T3 (es) | 2006-01-05 | 2015-01-15 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cánceres de colon, páncreas y estómago |
EP2371971B1 (en) | 2006-03-20 | 2013-11-27 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
WO2007112753A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EA201100811A1 (ru) * | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
WO2008061537A2 (en) * | 2006-11-23 | 2008-05-29 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US8697672B2 (en) | 2007-05-16 | 2014-04-15 | California Institute Of Technology | Microrna inhibition for the treatment of inflammation and myeloproliferative disorders |
JP2010529847A (ja) * | 2007-06-14 | 2010-09-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rna活性の調節のためのオリゴヌクレオチド |
MX2010001216A (es) | 2007-07-31 | 2010-04-30 | Univ Texas | Microarn que controla la expresion de miosina y la identidad de miofibras. |
WO2009018493A1 (en) | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | A micro-rna family that modulates fibrosis and uses thereof |
EP2650383A1 (en) | 2007-08-03 | 2013-10-16 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
ES2689508T3 (es) | 2007-10-04 | 2018-11-14 | Roche Innovation Center Copenhagen A/S | Micromir |
JP5535076B2 (ja) | 2007-10-29 | 2014-07-02 | レグルス・セラピューティクス・インコーポレイテッド | 肝臓癌を治療するための標的化ミクロrna |
US8513209B2 (en) | 2007-11-09 | 2013-08-20 | The Board Of Regents, The University Of Texas System | Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair |
WO2009091972A2 (en) * | 2008-01-18 | 2009-07-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
CN102027129B (zh) * | 2008-02-28 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
AU2009219190A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer |
US8361980B2 (en) * | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8202848B2 (en) | 2008-03-17 | 2012-06-19 | Board Of Regents, The University Of Texas System | Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration |
WO2009124295A2 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
US9068232B2 (en) * | 2008-08-06 | 2015-06-30 | Rosetta Genomics Ltd. | Gene expression signature for classification of kidney tumors |
WO2010033247A2 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
ES2572361T3 (es) * | 2008-12-31 | 2016-05-31 | Roche Innovation Ct Copenhagen As | Utilización de oligómeros de ANB antisentido de ApoB para el tratamiento de síndromes coronarios agudos |
CA2751489A1 (en) | 2009-02-04 | 2010-08-12 | Board Of Regents, The University Of Texas System | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
CA2753481A1 (en) * | 2009-02-25 | 2010-09-02 | Cepheid | Methods of detecting lung cancer |
JP5773535B2 (ja) | 2009-04-24 | 2015-09-02 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | インターフェロンに非応答性のhcv患者の治療のための医薬組成物 |
US8592388B2 (en) | 2009-05-20 | 2013-11-26 | Eth Zurich | Targeting MicroRNAs for metabolic disorders |
WO2010135714A2 (en) * | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
WO2011017089A1 (en) * | 2009-07-27 | 2011-02-10 | The Regents Of The University Of Colorado, A Body Corporate | Mirna inhibition of six1 expression |
ES2531964T3 (es) * | 2009-08-06 | 2015-03-23 | Universiteit Maastricht | Medios y métodos para contrarrestar, demorar y/o prevenir cambios adversos del metabolismo energético en enfermedades del corazón |
US8822144B2 (en) | 2009-08-19 | 2014-09-02 | Rosetta Genomics Ltd. | Compositions and methods for prognosis and treatment of prostate cancer |
FR2953220B1 (fr) | 2009-12-01 | 2012-11-23 | Oreal | Signature microarn de la differenciation epidermique et utilisations |
EP2476758A4 (en) * | 2009-09-07 | 2013-04-03 | Yoshiki Murakami | METHOD FOR PREDICTING THE THERAPEUTIC EFFECT ON CHRONIC HEPATITIS C |
US20120231970A1 (en) * | 2009-09-30 | 2012-09-13 | Japan Health Sciences Foundation | Colon cancer marker and method for testing for colon cancer |
EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
EP2499239A1 (en) * | 2009-11-11 | 2012-09-19 | Sanford-Burnham Medical Research Institute | METHOD FOR GENERATION AND REGULATION OF iPS CELLS AND COMPOSITIONS THEREOF |
CN101798594A (zh) * | 2009-11-13 | 2010-08-11 | 北京命码生科科技有限公司 | 检测牛乳质量的标志物、检测方法、生物芯片和试验盒 |
WO2011063382A1 (en) | 2009-11-23 | 2011-05-26 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
US20120302626A1 (en) | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
WO2011085276A2 (en) * | 2010-01-09 | 2011-07-14 | The Translational Genomics Research Institute | Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer |
US8841269B2 (en) * | 2010-02-23 | 2014-09-23 | Creighton University | Polynucleotides for use in treating and diagnosing cancers |
AU2011219029B2 (en) * | 2010-02-26 | 2017-02-02 | Columbia University | Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets |
US8906875B2 (en) * | 2010-03-12 | 2014-12-09 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
EP2865765B1 (en) * | 2010-04-20 | 2016-08-17 | Hummingbird Diagnostics GmbH | Complex miRNA sets as novel biomarkers for an acute coronary syndrome |
CN102140462B (zh) * | 2010-04-29 | 2013-06-12 | 苏州吉玛基因股份有限公司 | 人miR-1260反义核酸及其应用 |
WO2011146937A1 (en) * | 2010-05-21 | 2011-11-24 | The Translational Genomics Research Institute | Methods and kits useful in diagnosing nsclc |
JP6109069B2 (ja) * | 2010-06-04 | 2017-04-05 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | miR−378による代謝調節 |
WO2011163214A2 (en) * | 2010-06-21 | 2011-12-29 | Diogenix, Inc. | Microrna profiles for evaluating multiple sclerosis |
EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
CN102002494B (zh) * | 2010-07-08 | 2012-12-12 | 浙江理工大学 | microRNA生物标志物及其用途 |
GB201012418D0 (en) | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
US8815826B2 (en) | 2010-07-23 | 2014-08-26 | Regulus Therapeutics, Inc. | Targeting microRNAs for the treatment of fibrosis |
US8859519B2 (en) | 2010-08-25 | 2014-10-14 | The General Hospital Corporation | Methods targeting miR-33 microRNAs for regulating lipid metabolism |
CN102399852A (zh) * | 2010-09-08 | 2012-04-04 | 上海市公共卫生临床中心 | 用于预测干扰素治疗慢性乙型肝炎疗效的血浆miRNA谱及检测试剂盒 |
US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
EP2637673B1 (en) | 2010-11-12 | 2016-10-26 | The Ohio State University Research Foundation | Methods related to microrna-21 and mismatch repair in colorectal cancer |
EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
KR20140004646A (ko) | 2010-12-15 | 2014-01-13 | 미라젠 세러퓨틱스 | 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제 |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
US9045749B2 (en) | 2011-01-14 | 2015-06-02 | The General Hospital Corporation | Methods targeting miR-128 for regulating cholesterol/lipid metabolism |
JP2014513521A (ja) * | 2011-01-26 | 2014-06-05 | セファイド | 肺癌を検出する方法 |
CN102643813B (zh) * | 2011-02-18 | 2015-07-29 | 中国科学院上海药物研究所 | 人miR-504的反义寡聚核苷酸及其应用 |
CN102643808B (zh) * | 2011-02-18 | 2016-01-20 | 中国科学院上海药物研究所 | 人miR-1539的反义寡聚核苷酸及其应用 |
CN102643809B (zh) * | 2011-02-18 | 2016-01-20 | 中国科学院上海药物研究所 | 人miR-1274b的反义寡聚核苷酸及其应用 |
CN102643811B (zh) * | 2011-02-18 | 2015-12-09 | 中国科学院上海药物研究所 | 人miR-1229的反义寡聚核苷酸及其应用 |
CN102643814B (zh) * | 2011-02-18 | 2015-06-17 | 中国科学院上海药物研究所 | 人miR-431的反义寡聚核苷酸及其应用 |
CN102643806B (zh) * | 2011-02-18 | 2016-08-03 | 中国科学院上海药物研究所 | 人miR-1913的反义寡聚核苷酸及其应用 |
CN102643810B (zh) * | 2011-02-18 | 2015-12-16 | 中国科学院上海药物研究所 | 人miR-299-5p的反义寡聚核苷酸及其应用 |
WO2012139028A2 (en) * | 2011-04-06 | 2012-10-11 | The Trustees Of Princeton University | Anti-viral combination therapy |
WO2012145374A1 (en) | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
SI3211082T1 (sl) * | 2011-04-25 | 2021-08-31 | Sanofi | Spojine mikroRNA in postopki za spreminjanje delovanja MIR-21 |
WO2012149557A1 (en) * | 2011-04-28 | 2012-11-01 | New York University | miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION |
KR101800243B1 (ko) | 2011-06-22 | 2017-12-20 | (주)아모레퍼시픽 | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 |
WO2012175733A1 (en) | 2011-06-23 | 2012-12-27 | Santaris Pharma A/S | Hcv combination therapy |
WO2012175357A1 (en) * | 2011-06-24 | 2012-12-27 | Syddansk Universitet | Modulation of microrna-138 for the treatment of bone loss |
WO2013000856A1 (en) | 2011-06-30 | 2013-01-03 | Santaris Pharma A/S | Hcv combination therapy |
US20140113958A1 (en) * | 2011-06-30 | 2014-04-24 | Stella Aps | HCV Combination Therapy |
CN102851282B (zh) * | 2011-06-30 | 2014-10-08 | 上海市肿瘤研究所 | 用于区分原发性肺癌与癌旁组织的microRNA标志物 |
WO2013013165A2 (en) * | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
WO2013031704A1 (ja) * | 2011-08-29 | 2013-03-07 | 学校法人新潟科学技術学園新潟薬科大学 | ヒト白血病細胞のアポトーシスを誘導するヘプタマー型スモールガイド核酸 |
EP2755663A4 (en) * | 2011-09-13 | 2015-10-07 | Ottawa Hospital Res Inst | INHIBITORS OF MICRO-ARNMICRORNA INHIBITORS |
WO2013040429A1 (en) | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
KR20140091688A (ko) | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
AU2012322788B2 (en) | 2011-10-11 | 2018-01-04 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
WO2013068348A1 (en) | 2011-11-07 | 2013-05-16 | Santaris Pharma A/S | Lna oligomers for improvement in hepatic function |
JP2014533099A (ja) | 2011-11-07 | 2014-12-11 | ステラ・アンパルトセルスカブStella Aps | Hcv+患者におけるミクロrna−122阻害剤の有効性をチェックするための予測方法 |
US9745578B2 (en) | 2011-11-30 | 2017-08-29 | Cedars-Sinai Medical Center | Targeting microRNA miR-409-3P to treat prostate cancer |
WO2013082499A1 (en) * | 2011-11-30 | 2013-06-06 | Cedars-Sinai Medical Center | Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
US20140351963A1 (en) * | 2011-12-10 | 2014-11-27 | Ohio State Innovation Foundation | MiRNAs Useful to Reduce Lung Cancer Tumorigenesis and Chemotherapy Resistance and Related Compositions and Methods |
JP2015501843A (ja) | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
US20140356459A1 (en) * | 2011-12-15 | 2014-12-04 | Oncostamen S.R.L. | Micrornas and uses thereof |
EP2794924B1 (en) * | 2011-12-22 | 2019-02-06 | Baylor Research Institute | Identification of mirna signatures in human colorectal cancer |
AU2013209477B2 (en) | 2012-01-20 | 2016-12-08 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
BR112014026639A8 (pt) * | 2012-04-25 | 2018-01-16 | Regulus Therapeutics Inc | compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto. |
WO2013170146A1 (en) | 2012-05-10 | 2013-11-14 | Uab Research Foundation | Methods and compositions for modulating mir-204 activity |
CN104540947A (zh) | 2012-05-16 | 2015-04-22 | Rana医疗有限公司 | 用于调节smn基因家族表达的组合物和方法 |
JP2015523853A (ja) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Atp2a2発現を調節するための組成物及び方法 |
US20150133362A1 (en) | 2012-05-16 | 2015-05-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
CA2873797A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating utrn expression |
BR112014028631A2 (pt) | 2012-05-16 | 2017-10-17 | Rana Therapeutics Inc | composições e métodos para modulação da expressão da família de genes da hemoglobina |
CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
ES2801875T3 (es) | 2012-06-21 | 2021-01-14 | Miragen Therapeutics Inc | Inhibidores basados en oligonucleótidos que comprenden un motivo de ácido nucleico bloqueado |
US9163235B2 (en) * | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
EP2882496B1 (en) * | 2012-08-13 | 2019-10-09 | The Rockefeller University | Treatment and diagnosis of melanoma |
CN103627704A (zh) * | 2012-08-30 | 2014-03-12 | 苏州博泰安生物科技有限公司 | 前列腺癌分子标志物miR-19a及其应用 |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
US9493838B2 (en) | 2012-10-10 | 2016-11-15 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers and treatments for heart failure |
US9267139B2 (en) | 2012-10-11 | 2016-02-23 | Georgia Regents Research Institute, Inc. | Compositions and methods for treating musculoskeletal diseases and disorders |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
US9944991B2 (en) | 2012-11-02 | 2018-04-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies |
US9909128B2 (en) * | 2012-11-15 | 2018-03-06 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
DK2920304T3 (da) | 2012-11-15 | 2019-05-13 | Roche Innovation Ct Copenhagen As | Oligonukleotidkonjugater |
EP2733220B1 (en) * | 2012-11-16 | 2017-10-18 | Siemens Aktiengesellschaft | Novel miRNA as a diagnostic marker for Alzheimer's Disease |
US10011873B2 (en) | 2012-11-16 | 2018-07-03 | Universitat Des Saarlandes | Diagnostic miRNA markers for Parkinson disease |
EP2733219B1 (en) | 2012-11-16 | 2017-09-20 | Siemens Aktiengesellschaft | Diagnostic miRNA markers for Alzheimer |
WO2014108759A1 (en) | 2013-01-14 | 2014-07-17 | Pierfrancesco Tassone | INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA |
ES2606636T3 (es) * | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
RU2649367C2 (ru) * | 2013-01-30 | 2018-04-02 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты углевода и lna-олигонуклеотида |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
EP2964783B1 (en) * | 2013-03-06 | 2018-08-01 | Royal College of Surgeons in Ireland | Diagnosis and treatment of metabolic disorders |
KR101465319B1 (ko) * | 2013-03-08 | 2014-11-28 | 서울대학교산학협력단 | 마이크로 rna 분해 엘리먼트 및 그 용도 |
CN105188715B (zh) | 2013-03-15 | 2018-12-25 | 米拉根医疗股份有限公司 | Mir-145的锁定核酸抑制剂及其用途 |
WO2014145142A2 (en) * | 2013-03-15 | 2014-09-18 | Miles Gregory | Method of improving survival in cancer |
CA2909868C (en) | 2013-05-01 | 2021-10-19 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロRNA化合物およびmiR−122をモジュレートする方法 |
CN103290010B (zh) * | 2013-05-16 | 2015-09-16 | 南京市妇幼保健院 | 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-375及其应用 |
EP3007706A4 (en) * | 2013-06-12 | 2017-05-17 | New York University | Anti-mir-27b and anti-mir-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases |
US9976140B2 (en) * | 2013-06-14 | 2018-05-22 | Joslin Diabetes Center, Inc. | Microrna and uses in brown fat differentiation |
EP3013958B1 (en) * | 2013-06-25 | 2019-12-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Glucan-encapsulated sirna for treating type 2 diabetes mellitus |
RS59986B1 (sr) | 2013-06-27 | 2020-03-31 | Roche Innovation Ct Copenhagen As | Antisens oligomeri i konjugati koji ciljno deluju na pcsk9 |
WO2015006287A2 (en) * | 2013-07-08 | 2015-01-15 | International Dehydrated Foods, Inc. | Compositions prepared from poultry and methods of their use |
US11478504B2 (en) | 2013-07-08 | 2022-10-25 | International Dehydrated Foods, Inc. | Compositions and methods for preventing/treating metabolic syndrome |
CN104342439B (zh) * | 2013-07-23 | 2017-06-23 | 中国科学院遗传与发育生物学研究所 | miR‑7及其应用 |
JP2016534035A (ja) | 2013-10-04 | 2016-11-04 | ラナ セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症を治療するための組成物及び方法 |
EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
HUE039721T2 (hu) * | 2014-01-08 | 2019-02-28 | Hadasit Med Res Service | Mir-122 |
CN104774914B (zh) * | 2014-01-09 | 2018-01-09 | 复旦大学附属儿科医院 | 胆道闭锁及淤胆型婴儿肝炎综合征的microRNA血清标志物检测及其应用 |
CA2939120A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104974987B (zh) * | 2014-04-04 | 2018-06-19 | 宁夏医科大学 | 微小分子RNA-1247-5p作为新型肿瘤治疗分子靶标的用途 |
CN103937888B (zh) * | 2014-04-14 | 2016-08-17 | 上海交通大学 | 鉴别胃癌的血浆microRNA标志物的筛选与应用 |
CN103940998B (zh) * | 2014-05-04 | 2016-04-20 | 山东大学 | 血清microRNA作为肝细胞癌转移的早期诊断标志物的应用 |
JP6841661B2 (ja) * | 2014-06-13 | 2021-03-10 | ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン | 骨折および骨障害の診断および治療のための組成物および方法 |
WO2015200697A1 (en) | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
JP6819907B2 (ja) * | 2014-07-31 | 2021-01-27 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | 修飾抗mir−138オリゴヌクレオチド |
MX2017001674A (es) * | 2014-08-04 | 2017-08-10 | Miragen Therapeutics Inc | Inhibidores de myh7b y usos de los mismos. |
US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
CA2966044A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
US10206955B2 (en) * | 2014-11-05 | 2019-02-19 | Emory University | Compositions of ascorbic acid and bone morphogenetic protein 4 (BMP-4) for cell growth and uses related thereo |
US20180291374A1 (en) * | 2014-11-12 | 2018-10-11 | The General Hospital Corporation | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF |
AU2015349638A1 (en) * | 2014-11-21 | 2017-06-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
AU2015364508A1 (en) | 2014-12-18 | 2017-07-06 | Alnylam Pharmaceuticals, Inc. | ReversirTM compounds |
EA201791644A1 (ru) | 2015-01-20 | 2018-01-31 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-92 и их применение |
US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
WO2016138287A1 (en) | 2015-02-25 | 2016-09-01 | Washington University | METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs |
WO2016145008A2 (en) * | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Mirna for treatment of breast cancer |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
WO2016160882A1 (en) * | 2015-04-01 | 2016-10-06 | Baylor Research Institute | Methods for diagnosing and treating colorectal cancer using mirna549a |
WO2016164463A1 (en) | 2015-04-07 | 2016-10-13 | The General Hospital Corporation | Methods for reactivating genes on the inactive x chromosome |
EP3303590A4 (en) | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
US20180161357A1 (en) * | 2015-06-05 | 2018-06-14 | MiRagen Therapeutics, Inc. | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) |
WO2016210241A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
CN114552261A (zh) | 2015-07-07 | 2022-05-27 | 安费诺富加宜(亚洲)私人有限公司 | 电连接器 |
US10457941B2 (en) | 2015-08-20 | 2019-10-29 | ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE | Methods and compositions to treat liver diseases and conditions |
DK3341479T3 (da) | 2015-08-24 | 2020-02-24 | Roche Innovation Ct Copenhagen As | LNA-G-Proces |
EP3355932B1 (en) | 2015-10-02 | 2023-04-12 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
WO2017067970A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
EP3377086B1 (en) | 2015-11-19 | 2024-05-01 | The Brigham and Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3419665B1 (en) | 2016-02-25 | 2024-10-30 | The Brigham and Women's Hospital, Inc. | Treatment methods for fibrosis targeting smoc2 |
EP3430021A1 (en) | 2016-03-18 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Acyl-protected l-lna-guanosine monomers |
WO2017192959A2 (en) * | 2016-05-05 | 2017-11-09 | The Research Foundation For The State University Of New York | Therapeutically modulating apob and apoai |
CN109311925B (zh) | 2016-05-12 | 2022-06-03 | 罗氏创新中心哥本哈根有限公司 | 立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联 |
EP3254683A1 (en) | 2016-06-06 | 2017-12-13 | Medizinische Hochschule Hannover | Medicament for the treatment of acute liver failure |
WO2017216325A1 (en) | 2016-06-17 | 2017-12-21 | F. Hoffmann-La Roche Ag | In vitro nephrotoxicity screening assay |
CN109328236B (zh) | 2016-06-17 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 体外肾毒性筛选测定法 |
CA3030701A1 (en) | 2016-07-11 | 2018-01-18 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
EP3532638A4 (en) | 2016-10-31 | 2020-07-29 | University of Massachusetts | TARGETING MICROARN-101-3 P IN CARCINOTHERAPY |
CA3044896A1 (en) * | 2016-12-05 | 2018-06-14 | Charles R. ALLERSON | Modified oligonucleotides for treatment of polycystic kidney disease |
US11746381B2 (en) | 2017-03-10 | 2023-09-05 | Cancer Diagnostics Research Innvovations, LLC | Methods for diagnosing and treating gastric cancer using miRNA expression |
JP7164540B2 (ja) | 2017-03-29 | 2022-11-01 | ロシュ イノベーション センター コペンハーゲン エーエス | 立体的に規定されたホスホロチオエートオリゴヌクレオチドの調製のための直交保護基 |
JP7198768B2 (ja) | 2017-03-29 | 2023-01-04 | ロシュ イノベーション センター コペンハーゲン エーエス | UnyLinker迅速切断方法 |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
WO2019002237A1 (en) | 2017-06-28 | 2019-01-03 | Roche Innovation Center Copenhagen A/S | METHOD OF MULTIPLE COUPLING AND OXIDATION |
KR101871920B1 (ko) | 2017-08-04 | 2018-07-02 | (주)아모레퍼시픽 | 마이크로 rna를 포함하는 조성물 |
CA3073213A1 (en) | 2017-08-17 | 2019-02-21 | Alnylam Pharmaceuticals, Inc. | Tunable reversir tm compounds |
JP2021502059A (ja) | 2017-10-13 | 2021-01-28 | ロシュ イノベーション センター コペンハーゲン エーエス | 部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法 |
CN114512840B (zh) | 2017-10-30 | 2024-06-25 | 安费诺富加宜(亚洲)私人有限公司 | 低串扰卡缘连接器 |
US11413288B2 (en) | 2017-11-01 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
US10601181B2 (en) | 2017-12-01 | 2020-03-24 | Amphenol East Asia Ltd. | Compact electrical connector |
MX2020005754A (es) | 2017-12-22 | 2020-08-20 | Roche Innovation Ct Copenhagen As | Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato. |
CN111757936A (zh) | 2017-12-22 | 2020-10-09 | 罗氏创新中心哥本哈根有限公司 | 包含二硫代磷酸酯核苷间连接的寡核苷酸 |
EP4092118A1 (en) | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Novel thiophosphoramidites |
CN109985243B (zh) * | 2017-12-29 | 2021-06-29 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
CN111836624A (zh) | 2018-01-12 | 2020-10-27 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
EP3765610A4 (en) * | 2018-03-14 | 2022-01-19 | Beth Israel Deaconess Medical Center | MICRO-RNA AND OBESITY |
WO2019209704A1 (en) * | 2018-04-23 | 2019-10-31 | Board Of Regents, The University Of Texas System | Microrna 584-5p compositions and methods for treating cancer |
US12005120B2 (en) | 2018-05-08 | 2024-06-11 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect |
CN109321655B (zh) * | 2018-05-17 | 2022-07-05 | 福建省肿瘤医院(福建省肿瘤研究所、福建省癌症防治中心) | Nkiras2基因调控区序列、调控序列及其在鼻咽癌中的应用 |
US20210220387A1 (en) | 2018-05-18 | 2021-07-22 | Hoffmann-La Roche, Inc. | Pharmaceutical compositions for treatment of microrna related diseases |
EP4122943B1 (en) | 2018-07-31 | 2024-05-29 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
MX2020013270A (es) | 2018-07-31 | 2021-02-18 | Roche Innovation Ct Copenhagen As | Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato. |
WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
WO2020047229A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
EP3620519A1 (en) | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
WO2020051398A1 (en) * | 2018-09-06 | 2020-03-12 | Aptamir Therapeutics, Inc. | Metabolic benefits of short mir-22 mirna antagomir therapies |
CN113169484A (zh) | 2018-10-09 | 2021-07-23 | 安费诺商用电子产品(成都)有限公司 | 高密度边缘连接器 |
TWM576774U (zh) | 2018-11-15 | 2019-04-11 | 香港商安費諾(東亞)有限公司 | 具有防位移結構之金屬殼體及其連接器 |
US11381015B2 (en) | 2018-12-21 | 2022-07-05 | Amphenol East Asia Ltd. | Robust, miniaturized card edge connector |
WO2020152303A1 (en) | 2019-01-25 | 2020-07-30 | F. Hoffmann-La Roche Ag | Lipid vesicle for oral drug delivery |
WO2020169696A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Novel phosphoramidites |
EP3927826A1 (en) | 2019-02-20 | 2021-12-29 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
TWM582251U (zh) * | 2019-04-22 | 2019-08-11 | 香港商安費諾(東亞)有限公司 | Connector set with built-in locking mechanism and socket connector thereof |
US20220193261A1 (en) * | 2019-04-30 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of pompe disease |
AU2020264760A1 (en) * | 2019-05-02 | 2021-11-11 | Celyad | Cells with multiplexed inhibitory RNA |
CN110283794B (zh) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | 重组溶瘤病毒以及制备方法、应用和药物 |
JP2022538868A (ja) | 2019-06-26 | 2022-09-06 | バイオーケストラ カンパニー, リミテッド | ミセルナノ粒子及びその使用 |
US10844383B1 (en) | 2019-09-18 | 2020-11-24 | Dasman Diabetes Institute | Microrna dyslipidemia inhibitor |
US11588277B2 (en) | 2019-11-06 | 2023-02-21 | Amphenol East Asia Ltd. | High-frequency electrical connector with lossy member |
US11799230B2 (en) | 2019-11-06 | 2023-10-24 | Amphenol East Asia Ltd. | High-frequency electrical connector with in interlocking segments |
ES2982346T3 (es) | 2019-12-13 | 2024-10-15 | Inspirna Inc | Sales metálicas y usos de las mismas |
US11058710B1 (en) | 2020-02-14 | 2021-07-13 | Dasman Diabetes Institute | MicroRNA ANGPTL3 inhibitor |
EP4114938A1 (en) * | 2020-03-04 | 2023-01-11 | The Trustees of Indiana University | Methods to re-engage a fetal wound healing pathway for adult skin repair |
CA3179768A1 (en) * | 2020-04-09 | 2021-10-14 | Biovista, Inc. | Compositions and methods for treating viral infections |
KR20230009965A (ko) * | 2020-05-11 | 2023-01-17 | 더 플로레이 인스티튜트 오브 뉴로사이언스 앤드 멘탈 헬스 | Syngap1에서 기능-상실 돌연변이와 연관된 장애를 치료하기 위한 조성물 및 방법 |
US11652307B2 (en) | 2020-08-20 | 2023-05-16 | Amphenol East Asia Electronic Technology (Shenzhen) Co., Ltd. | High speed connector |
CN212874843U (zh) | 2020-08-31 | 2021-04-02 | 安费诺商用电子产品(成都)有限公司 | 电连接器 |
WO2022245981A2 (en) * | 2021-05-18 | 2022-11-24 | Cornell University | Use of microrna mimics to inhibit or treat liver disease |
WO2023067038A1 (en) | 2021-10-22 | 2023-04-27 | Roche Innovation Center Copenhagen A/S | Process for oligonucleotide purification |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023170659A1 (en) | 2022-03-11 | 2023-09-14 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Breast cancer diagnostic and treatment |
JPWO2023190271A1 (da) | 2022-03-28 | 2023-10-05 | ||
KR102711428B1 (ko) * | 2022-04-28 | 2024-09-26 | 차의과학대학교 산학협력단 | 삼중음성유방암의 예방, 개선 또는 치료용 약학 조성물 |
US20230399644A1 (en) * | 2022-04-29 | 2023-12-14 | University Of Massachusetts | Selective rna-modulating agents |
CN114990159A (zh) * | 2022-05-18 | 2022-09-02 | 昆明理工大学 | 一种micorRNA206抑制HCV增殖的建立方法 |
WO2024033441A1 (en) * | 2022-08-09 | 2024-02-15 | Geg Tech | Transient expression system for rna |
WO2024033446A1 (en) * | 2022-08-09 | 2024-02-15 | Geg Tech | Transient expression system for rna, for gene editing |
WO2024033448A1 (en) * | 2022-08-09 | 2024-02-15 | Geg Tech | Transient expression system for rna, for vaccination |
WO2024033444A1 (en) * | 2022-08-09 | 2024-02-15 | Geg Tech | Transient expression system for rna, for cosmetic uses |
WO2024124218A1 (en) * | 2022-12-08 | 2024-06-13 | 1 Globe Health Institute Llc | Antisense rna (asrna) technology and use thereof |
WO2024124213A1 (en) * | 2022-12-08 | 2024-06-13 | 1Globe Health Institute Llc | Asymmetric short duplex rna with interspersed deoxyribonucleotides as a gene silencing technology and use thereof |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2806208A (en) | 1951-09-29 | 1957-09-10 | Columbia Broadcasting Syst Inc | Vacuum tube voltmeter |
US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
JPH06311885A (ja) | 1992-08-25 | 1994-11-08 | Mitsubishi Kasei Corp | C型肝炎ウイルス遺伝子に相補的なアンチセンス化合物 |
CA2143678A1 (en) | 1992-09-10 | 1994-03-17 | Kevin P. Anderson | Compositions and methods for treatment of hepatitis c virus-associated diseases |
US6423489B1 (en) * | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6433159B1 (en) * | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
EP0759979A4 (en) | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | ANTISENSE OLIGONUCLEOTIDES INHIBITION OF HEPATITIS C VIRUS |
US5919795A (en) * | 1995-06-07 | 1999-07-06 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion |
KR100334567B1 (ko) * | 1996-11-27 | 2002-05-03 | 디. 제이. 우드, 스피겔 알렌 제이 | 아포 비-분비/엠티피 억제성 아미드 |
WO1998039487A1 (en) * | 1997-03-05 | 1998-09-11 | Ribogene, Inc. | Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
CA2285613C (en) * | 1998-02-20 | 2008-03-25 | Decoma International Corp. | Mold clamp |
JP2002540118A (ja) | 1999-03-18 | 2002-11-26 | エクシコン エ/エス | キシロ−lna類似体 |
DK1163250T3 (da) | 1999-03-24 | 2006-11-13 | Exiqon As | Forbedret syntese af [2.2.1]bicyclonukleosider |
ES2283298T3 (es) | 1999-05-04 | 2007-11-01 | Santaris Pharma A/S | Analogos de l-ribo-lna. |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
WO2001025248A2 (en) | 1999-10-04 | 2001-04-12 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
IL139450A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
AU2001277170A1 (en) | 2000-07-25 | 2002-02-05 | Authentisure, Inc. | Unified trust model providing secure identification, authentication and validation of physical products and entities, and processing, storage, and exchange of information |
JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー/エス | プリンlna類似体の改善された合成方法 |
AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
AU2002317437A1 (en) | 2001-05-18 | 2002-12-03 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
WO2003070750A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | Rna interference mediated inhibition of hepatitis c virus |
DK1409497T3 (da) | 2001-07-12 | 2005-05-30 | Santaris Pharma As | Fremgangsmåde til fremstilling af LNA-phosphoramiditer |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
US7459461B2 (en) * | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
CA2484526C (en) | 2002-05-08 | 2009-10-13 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
WO2004014313A2 (en) * | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
UA79300C2 (en) | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
JP4986109B2 (ja) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | アポリポタンパク質b発現のアンチセンス調節 |
DK2284269T3 (da) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense-design |
US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
FR2848572B1 (fr) * | 2002-12-12 | 2005-12-09 | Univ Joseph Fourier | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
US20060247193A1 (en) | 2003-02-10 | 2006-11-02 | National Institute Of Advanced Industrial Science And Technology | Regulation of gene expression by dna interference |
EP1592793B2 (en) | 2003-02-10 | 2014-05-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of survivin expression |
US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US20080311556A1 (en) | 2003-08-07 | 2008-12-18 | Iversen Patrick L | Sense Antiviral Compound and Method for Treating Ssrna Viral Infection |
US20050142581A1 (en) | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
AU2004294567A1 (en) | 2003-11-26 | 2005-06-16 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
UA83510C2 (en) | 2003-12-09 | 2008-07-25 | Янссен Фармацевтика Н.В. | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
RU2377301C2 (ru) | 2003-12-23 | 2009-12-27 | Сантарис Фарма А/С | ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА |
EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
US20050182005A1 (en) * | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
US7772389B2 (en) | 2004-02-13 | 2010-08-10 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
DE102004015101B4 (de) | 2004-03-27 | 2012-04-26 | Eastman Kodak Co. | Verfahren und Sensoreinrichtung zum Steuern eines endlosen, eine Naht aufweisenden Transportmediums für eine Druckmaschine |
JP5192229B2 (ja) | 2004-04-07 | 2013-05-08 | エクシコン・アクティーゼルスカブ | microRNAおよび低分子干渉RNAの定量化のための新規方法 |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
BRPI0509979A (pt) | 2004-04-20 | 2007-10-16 | Genaco Biomedical Products Inc | método para detectar ncrna |
JP4943322B2 (ja) | 2004-05-04 | 2012-05-30 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 標的細胞中のウイルスゲノム量を減少させるための方法および組成物 |
US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
AU2005328382C1 (en) | 2004-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
FR2873694B1 (fr) | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
EP1913011B1 (en) | 2004-08-04 | 2016-11-02 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
SI2409713T1 (sl) | 2004-08-10 | 2015-10-30 | Genzyme Corporation | Oligonukleotidi za uporabo pri uravnavanju nivojev lipoproteinov in holesterola pri ljudeh |
JP5192234B2 (ja) * | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 化学修飾オリゴヌクレオチド |
WO2006027776A1 (en) | 2004-09-07 | 2006-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
NZ586217A (en) | 2004-09-24 | 2011-12-22 | Alnylam Pharmaceuticals Inc | RNAI modulation of APOB and uses thereof |
EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
WO2006053430A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
BRPI0607555A2 (pt) | 2005-04-19 | 2009-09-15 | Surface Logix Inc | inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b |
US20060265771A1 (en) * | 2005-05-17 | 2006-11-23 | Lewis David L | Monitoring microrna expression and function |
WO2006133022A2 (en) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
CA2618995A1 (en) | 2005-08-10 | 2007-02-22 | The Rockefeller University | Antagomirs for use in inhibiting mir-122 |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
EP1931780B1 (en) | 2005-08-29 | 2016-01-06 | Regulus Therapeutics Inc. | Antisense compounds having enhanced anti-microrna activity |
JP5523705B2 (ja) | 2005-08-29 | 2014-06-18 | レグルス・セラピューティクス・インコーポレイテッド | Mir−122aをモジュレートする使用方法 |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US20090118213A1 (en) | 2005-09-15 | 2009-05-07 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
CA2640058C (en) | 2006-01-27 | 2018-04-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
EA201100811A1 (ru) * | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
WO2007112753A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
WO2007136988A2 (en) | 2006-05-05 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of gccr |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
US7694029B2 (en) | 2006-08-02 | 2010-04-06 | International Business Machines Corporation | Detecting miscabling in a storage area network |
US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
KR20090054438A (ko) | 2006-09-15 | 2009-05-29 | 엔존 파마슈티컬즈, 인코포레이티드 | 양전하를 띄는 부분을 포함하는 고분자 컨쥬게이트 |
CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
WO2008057234A2 (en) | 2006-10-24 | 2008-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of t cell signaling threshold and t cell sensitivity to antigens |
WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
WO2008061537A2 (en) | 2006-11-23 | 2008-05-29 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
WO2008124384A2 (en) | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (da) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocycliske bicycliske nukleinsyreanaloge |
JP2010529847A (ja) | 2007-06-14 | 2010-09-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rna活性の調節のためのオリゴヌクレオチド |
US20090082297A1 (en) | 2007-06-25 | 2009-03-26 | Lioy Daniel T | Compositions and Methods for Regulating Gene Expression |
US20110009466A1 (en) | 2007-08-29 | 2011-01-13 | President And Fellows Of Harvard College | Methods of increasing gene expression through rna protection |
ES2689508T3 (es) * | 2007-10-04 | 2018-11-14 | Roche Innovation Center Copenhagen A/S | Micromir |
US8361980B2 (en) * | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
WO2010000665A1 (en) | 2008-06-30 | 2010-01-07 | Santaris Pharma A/S | Antidote oligomers |
US8398734B2 (en) | 2008-08-01 | 2013-03-19 | Twister B.V. | Cyclonic separator with a volute outlet duct |
EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
JP5773535B2 (ja) * | 2009-04-24 | 2015-09-02 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | インターフェロンに非応答性のhcv患者の治療のための医薬組成物 |
US8942209B2 (en) | 2009-08-12 | 2015-01-27 | Qualcomm Incorporated | Systems and methods for supporting an enhanced serving cell change when moving among different cell types |
EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
-
2008
- 2008-10-03 ES ES12191738.9T patent/ES2689508T3/es active Active
- 2008-10-03 EA EA201070421A patent/EA019939B1/ru not_active IP Right Cessation
- 2008-10-03 EP EP18185844.0A patent/EP3492594A1/en active Pending
- 2008-10-03 EP EP12191739.7A patent/EP2623599B1/en active Active
- 2008-10-03 ES ES08801379.2T patent/ES2463665T3/es active Active
- 2008-10-03 PL PL12191738T patent/PL2623598T3/pl unknown
- 2008-10-03 WO PCT/DK2008/000344 patent/WO2009043353A2/en active Application Filing
- 2008-10-03 US US12/681,587 patent/US8906871B2/en active Active
- 2008-10-03 WO PCT/DK2008/000345 patent/WO2009043354A2/en active Application Filing
- 2008-10-03 KR KR1020107009969A patent/KR101889518B1/ko active IP Right Grant
- 2008-10-03 MY MYPI2010001033A patent/MY156951A/en unknown
- 2008-10-03 EP EP08801378A patent/EP2205737B1/en not_active Revoked
- 2008-10-03 MX MX2010003299A patent/MX2010003299A/es active IP Right Grant
- 2008-10-03 DK DK12191739.7T patent/DK2623599T3/da active
- 2008-10-03 DK DK08801378.4T patent/DK2205737T3/da active
- 2008-10-03 US US12/681,591 patent/US8440637B2/en not_active Expired - Fee Related
- 2008-10-03 JP JP2010527323A patent/JP6035010B2/ja active Active
- 2008-10-03 CN CN200880110388.3A patent/CN101821391B/zh active Active
- 2008-10-03 CA CA2701547A patent/CA2701547C/en not_active Expired - Fee Related
- 2008-10-03 AU AU2008306327A patent/AU2008306327B2/en not_active Ceased
- 2008-10-03 EP EP08801379.2A patent/EP2203559B1/en not_active Not-in-force
- 2008-10-03 US US12/245,544 patent/US8288356B2/en active Active
- 2008-10-03 EP EP12191738.9A patent/EP2623598B1/en active Active
- 2008-10-03 ES ES08801378T patent/ES2406686T3/es active Active
- 2008-10-03 NZ NZ583677A patent/NZ583677A/en not_active IP Right Cessation
-
2010
- 2010-03-02 IL IL204254A patent/IL204254A/en not_active IP Right Cessation
- 2010-03-23 ZA ZA2010/02040A patent/ZA201002040B/en unknown
-
2014
- 2014-10-29 US US14/527,115 patent/US9790493B2/en active Active
-
2015
- 2015-01-23 JP JP2015011745A patent/JP6231029B2/ja active Active
-
2016
- 2016-03-08 IL IL244498A patent/IL244498A0/en unknown
-
2017
- 2017-09-15 US US15/705,739 patent/US10450564B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602008006301D1 (de) | Koaxialnadelanordnung | |
BRPI0821573A2 (pt) | benzofuropirimidonas | |
ATE501136T1 (de) | Imidazopyridinone | |
DK2159224T3 (da) | Bromphenylsubstituerede thiazolyldihydropyrimidiner | |
ATE514696T1 (de) | Diphenyl-dihydro-imidazopyridinone | |
DE602008002772D1 (de) | Polyvinylpyrrolidonpulverzusammensetzungen | |
DE112008003636A5 (de) | Mehrzuggruppierer | |
DE502007001207D1 (de) | Elektrosaugkopf | |
BRPI0814519A2 (pt) | Organopolissiloxano | |
BRPI0811451A2 (pt) | Exopolissacarídeo | |
DE602008000923D1 (de) | Einzelwaferätzgerät | |
DE602008000749D1 (de) | Buschschneider | |
BRPI0812840A2 (pt) | 2-imidazolinas | |
BRPI0815547A2 (pt) | Depsipeptídeos cícliocos | |
AT505058A3 (de) | Türschliesssystem | |
DE602008004695D1 (de) | Katalysatorträgerwabe | |
DE602008001234D1 (de) | Bandmaterialzuführvorrichtung | |
BRPI0812994A2 (pt) | Microbiocidas | |
DE602008005950D1 (de) | Münzvereinzeler | |
DE602008005589D1 (de) | Rliganden | |
DE112008001216A5 (de) | Magnetronplasmaanlage | |
DE502008001694D1 (de) | Mitfahrhubwagen | |
DE112008003094A5 (de) | Geomatte | |
DE602008001674D1 (de) | Wimpernwickler | |
DE602008006131D1 (de) | Schussfadeneintragdüse |